CagriSema REDEFINE 1 Target Analysis

A secondary, post hoc analysis of the 68-week REDEFINE 1 trial found that 30.3% of participants with week-68 data in the CagriSema group reached both a body mass index below 27 kg/m² and a waist-to-height ratio below 0.53. The corresponding proportions were 19.1% with semaglutide, 9.0% with cagrilintide and 3.3% with placebo^[1]. Treatment assignment came from a randomized trial, but these particular targets and their relationship with cardiometabolic measures were examined after the fact. They should not be read as validated rules for changing an individual's treatment.

What this REDEFINE 1 analysis asked

REDEFINE 1 randomized 3,417 adults without diabetes to CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg or placebo, alongside lifestyle intervention, for 68 weeks. Eligibility required a BMI of at least 30 kg/m², or at least 27 kg/m² with one or more obesity-related complications^[2]. CagriSema combines cagrilintide with semaglutide; this analysis did not evaluate either component outside the trial's studied regimen.

The new paper did not simply repeat the trial's average percentage weight change. Instead, investigators asked how many participants reached absolute body-size thresholds and whether those thresholds tracked with selected metabolic measures. BMI below 27 kg/m² and waist-to-height ratio below 0.53 were the main anthropometric targets. Those cutoffs were analytical choices, not prospectively tested treatment goals.

This distinction is central. Randomization supports comparisons among the assigned treatment groups, yet it does not validate a target chosen for a later analysis. Nor does reaching a threshold prove that the threshold itself caused better blood pressure or laboratory results.

The week-68 target results

Among participants with observed week-68 data, 41.0% in the CagriSema group reached BMI below 27 kg/m². The proportions were 24.5% for semaglutide, 13.5% for cagrilintide and 6.0% for placebo. For waist-to-height ratio below 0.53, the respective values were 34.8%, 25.0%, 10.8% and 6.4%^[3].

The stricter result required both targets at once. It was reached by 437 of 1,444 participants with data in the CagriSema group, 42 of 220 in the semaglutide group, 20 of 223 in the cagrilintide group and 15 of 451 in the placebo group^[3]. Those denominators matter because they are smaller than the numbers originally randomized. The published statistical approach addressed missing and off-treatment data under a missing-at-random assumption, while the table's observed counts show who had measurements at that point.

Absolute thresholds answer a different question from percentage weight loss. A person starting at a higher BMI may lose a substantial percentage without crossing BMI 27, while someone starting closer to the threshold may cross it with a smaller change. Waist-to-height ratio adds information about central body size, but neither measure captures every health outcome or personal treatment priority.

What the cardiometabolic comparison means

Investigators also assessed whether reaching the anthropometric targets corresponded with four predefined outcomes: normoglycaemia, blood pressure below 130/80 mmHg, triglycerides below 1.7 mmol/L and sex-specific HDL cholesterol thresholds^[2]. BMI and waist-to-height ratio performed similarly as indicators across those measures. More than 60% of the subset reaching both anthropometric targets also met the cardiometabolic outcomes described by the authors^[3].

Association is not a treatment rule. Participants who crossed the body-size thresholds may differ in other ways from those who did not, and the trial did not randomize people to a target-based care strategy. The analysis therefore cannot show that escalating or reducing treatment until a specific BMI or waist-to-height ratio is reached will improve clinical outcomes.

The outcomes were risk markers measured at week 68. They were not a test of whether the proposed thresholds prevent heart attacks, strokes or death over years of follow-up. Readers looking for the broader evidence around the GLP-1 component can use the semaglutide research overview, but this post hoc paper answers the narrower target-attainment question.

Why the post hoc design limits interpretation

The full text labels the findings hypothesis-generating. Its limitations include the post hoc design, reduced capacity for statistical comparisons and the fact that participants were not treated to the proposed targets. The cutoffs came from an adult population aged 18 to 60 years, so their applicability to older adults remains uncertain^[3].

Representation also narrows generalizability. At baseline, the trial population was 67.6% female and 72.0% White, with a mean age of 47 years and mean BMI of 37.9 kg/m². Results from this population may not transfer cleanly to groups with different ages, backgrounds or starting body composition.

Missing-data assumptions add another boundary. The analysis assumed missing values were missing at random and used model-based imputation for binary endpoints. That is a standard statistical approach, but it cannot guarantee that people without measurements followed the same pattern as those observed. The large difference between randomized and observed week-68 counts makes the assumption worth keeping visible.

Sponsor involvement and conflicts

Novo Nordisk sponsored the study and was responsible for its design, protocol preparation and statistical analyses. The company also paid for medical writing and editorial support. Three authors were Novo Nordisk employees and shareholders, while several other authors disclosed consulting, speaking or research relationships with drug manufacturers^[3].

Sponsor involvement does not invalidate a result. It does increase the value of transparent methods, accessible data and independent replication. Here, the authors state that qualified researchers may request access to anonymized clinical study data through a proposal and review process rather than receiving unrestricted public access.

What the findings can support now

The analysis supports a testable research idea: absolute BMI and waist-to-height thresholds may add information to percentage weight loss when obesity trials evaluate metabolic change. It also documents that more participants assigned to CagriSema reached the selected thresholds than participants in the other trial groups. These are group-level findings from one post hoc analysis.

Prospective studies would need to define the targets in advance, enroll more diverse populations and test whether target-guided decisions improve outcomes that matter to patients. Longer follow-up would help determine whether crossing a week-68 threshold predicts durable health benefit. Until then, BMI and waist-to-height ratio remain measurements to interpret alongside clinical history, laboratory findings and patient priorities, not stand-alone instructions.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.